HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Opioid-Withdrawal 'Aids' Warrant Immediate FDA, FTC Action – CSPI

This article was originally published in The Rose Sheet

Executive Summary

FDA and the Federal Trade Commission should bring immediate enforcement action against marketers of non-kratom dietary supplements promoted as opioid-withdrawal aids, says the Center for Science in the Public Interest in letters to the agency and commission Dec. 8. The nonprofit identified eight supplement products making opioid-withdrawal claims without sufficient science to support the statements.


Related Content

Poppy Seed Tea Latest Catch In FDA Enforcement Net For Opioid Claims
Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue
Kratom Supplement Marketers Dispute FDA Warning, Ask For Review
FDA Turns Kratom's Future In US Dietary Supplement Market Into History
Opiate Addiction Remedy Claims Could Face FTC Substantiation Test
Sturman Leads Nature's Bounty For New Owner: Health And Wellness Industry News





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts